We bring you the latest news from the healthcare about the health care in the United Kingdom.

vrijdag 27 april 2018

The Lancet: [Comment] Quality of life after multicatheter breast brachytherapy

[Comment] Quality of life after multicatheter breast brachytherapy
As the risk of breast cancer recurrence has fallen, interest has grown in understanding the impact of different treatment options on patients' quality of life. The initial trials1 that established breast conservation as an alternative to mastectomy found that adjuvant irradiation to the whole breast improved disease control. More recent trials have pursued the innovative idea of targeting just part of the breast with radiotherapy in selected patients. Partial breast irradiation can be delivered with a variety of techniques, ranging from external-beam treatment to brachytherapy, using multicatheter or single-entry balloon or strut-based devices.
Read more

[Comment] Cystic fibrosis: a gastrointestinal cancer syndrome
Cystic fibrosis is the most common autosomal recessive disease among white populations with an incidence of around 1 in 3500 births. The mean prevalence of cystic fibrosis in the USA and Europe is similar (0·74 vs 0·80 per 10 000 individuals).
Read more

[Articles] Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial
The safety and tolerability of balixafortide plus eribulin seems to be similar to that of eribulin or balixafortide monotherapy, and the preliminary activity of the combination seems promising in patients with HER-negative metastatic breast cancer. The results suggest that balixafortide plus eribulin has potential to provide a new therapeutic option in heavily pretreated patients with metastatic breast cancer and warrants further investigation in randomised trials.
Read more

[News] UK to align with EU clinical trial rules post-Brexit
The UK Government has confirmed that it will align as closely as possible with the EU Clinical Trial Regulation (CTR) after Brexit. The CTR was passed in 2014, and the UK was instrumental in its development. The CTR aims to harmonise and streamline the clinical trial approval process across the EU. Implementation has been delayed until the portal and database required by the new system are operational, which is expected to happen sometime next year (2019). After Brexit, the UK will automatically adopt EU laws that have been implemented.
Read more

[News] American Association for Cancer Research Annual Meeting 2018
CMP-001, a TLR9 agonist packaged in a virus-like particle, plus pembrolizumab showed encouraging activity in patients with metastatic melanoma refractory or resistant to anti-PD-1 treatment. Mohammed Milhem (University of Iowa, Iowa City, IA, USA) and colleagues treated 68 patients with this combination therapy in a phase 1b trial. The primary endpoint was the recommended phase 2 dose for the combination. The safety analysis (data cutoff Dec 31, 2018) in 63 patients showed a manageable acute toxicity profile.
Read more